Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$15.30 USD
-0.38 (-2.42%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $15.32 +0.02 (0.13%) 4:52 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
URGN 15.30 -0.38(-2.42%)
Will URGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for URGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for URGN
Does Urogen Pharma (URGN) Have the Potential to Rally 171.05% as Wall Street Analysts Expect?
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
URGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High?
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
Other News for URGN
UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
TD Cowen Sticks to Their Buy Rating for Urogen Pharma (URGN)
Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN), AnaptysBio (ANAB) and Sarepta Therapeutics (SRPT)
Maintaining Neutral: Paul Choi’s Hold Rating on UroGen Pharma Amidst Steady Projections and Upcoming FDA Review
UroGen Pharma stock slumps after pricing stock and warrants offering